778 related articles for article (PubMed ID: 33892169)
1. Metabolic-associated fatty liver disease and lipoprotein metabolism.
Heeren J; Scheja L
Mol Metab; 2021 Aug; 50():101238. PubMed ID: 33892169
[TBL] [Abstract][Full Text] [Related]
2. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.
Lee JJ; Lambert JE; Hovhannisyan Y; Ramos-Roman MA; Trombold JR; Wagner DA; Parks EJ
Am J Clin Nutr; 2015 Jan; 101(1):34-43. PubMed ID: 25527748
[TBL] [Abstract][Full Text] [Related]
3. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.
Taher J; Baker C; Alvares D; Ijaz L; Hussain M; Adeli K
Endocrinology; 2018 Sep; 159(9):3340-3350. PubMed ID: 30052880
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
5. Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.
Alves-Bezerra M; Li Y; Acuña M; Ivanova AA; Corey KE; Ortlund EA; Cohen DE
Hepatology; 2019 Aug; 70(2):496-510. PubMed ID: 30516845
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
7. The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis.
Heida A; Gruben N; Catrysse L; Koehorst M; Koster M; Kloosterhuis NJ; Gerding A; Havinga R; Bloks VW; Bongiovanni L; Wolters JC; van Dijk T; van Loo G; de Bruin A; Kuipers F; Koonen DPY; van de Sluis B
Mol Metab; 2021 Dec; 54():101349. PubMed ID: 34626855
[TBL] [Abstract][Full Text] [Related]
8. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
Yang M; Liu Q; Huang T; Tan W; Qu L; Chen T; Pan H; Chen L; Liu J; Wong CW; Lu WW; Guan M
Theranostics; 2020; 10(24):10874-10891. PubMed ID: 33042259
[No Abstract] [Full Text] [Related]
9. Lipid Disorders and Metabolic-Associated Fatty Liver Disease.
Anwar SD; Foster C; Ashraf A
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):445-457. PubMed ID: 37495336
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.
Kawano Y; Cohen DE
J Gastroenterol; 2013 Apr; 48(4):434-41. PubMed ID: 23397118
[TBL] [Abstract][Full Text] [Related]
11. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
[TBL] [Abstract][Full Text] [Related]
12. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.
Lee E; Korf H; Vidal-Puig A
J Hepatol; 2023 May; 78(5):1048-1062. PubMed ID: 36740049
[TBL] [Abstract][Full Text] [Related]
13. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.
Fabbrini E; Mohammed BS; Magkos F; Korenblat KM; Patterson BW; Klein S
Gastroenterology; 2008 Feb; 134(2):424-31. PubMed ID: 18242210
[TBL] [Abstract][Full Text] [Related]
14. Metabolic drivers of non-alcoholic fatty liver disease.
Bence KK; Birnbaum MJ
Mol Metab; 2021 Aug; 50():101143. PubMed ID: 33346069
[TBL] [Abstract][Full Text] [Related]
15. Exercise increases myocardial free fatty acid oxidation in subjects with metabolic dysfunction-associated fatty liver disease.
Risikesan J; Heebøll S; Kumarathas I; Funck KL; Søndergaard E; Johansen RF; Ringgaard S; Tolbod LP; Johannsen M; Kanstrup HL; Grønbæk H; Frystyk J; Gormsen LC; Nielsen S
Atherosclerosis; 2023 May; 372():10-18. PubMed ID: 37011565
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.
Badmus OO; Hillhouse SA; Anderson CD; Hinds TD; Stec DE
Clin Sci (Lond); 2022 Sep; 136(18):1347-1366. PubMed ID: 36148775
[TBL] [Abstract][Full Text] [Related]
17. Role of Insulin Resistance in MAFLD.
Sakurai Y; Kubota N; Yamauchi T; Kadowaki T
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923817
[TBL] [Abstract][Full Text] [Related]
18. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
Mashek DG
Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
[TBL] [Abstract][Full Text] [Related]
19. Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes.
Carlier A; Phan F; Szpigel A; Hajduch E; Salem JE; Gautheron J; Le Goff W; Guérin M; Lachkar F; Ratziu V; Hartemann A; Ferré P; Foufelle F; Bourron O
Cell Rep Med; 2020 Dec; 1(9):100154. PubMed ID: 33377125
[TBL] [Abstract][Full Text] [Related]
20. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD.
Huang KT; Chen KD; Hsu LW; Kung CP; Li SR; Chen CC; Chiu KW; Goto S; Chen CL
Nutrients; 2020 Jan; 12(1):. PubMed ID: 31968655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
